BioXcel Therapeutics FY2025 net revenue drops 72% to $642,000; net loss widens to $69.9 million

Reuters03-27
BioXcel <a href="https://laohu8.com/S/LENZ">Therapeutics</a> FY2025 net revenue drops 72% to $642,000; net loss widens to $69.9 million
  • BioXcel published a fourth-quarter and full-year 2025 earnings release reporting IGALMI net revenue of USD 256,000 in Q4 and USD 642,000 for FY 2025, down 30.05% and 71.67%, respectively.
  • Cost of goods sold was USD 32,000 in Q4 and USD 164,000 for FY 2025, down 96.15% and 92.35%, respectively, primarily due to lower charges for reserves for excess or obsolete inventory.
  • R&D expense totaled USD 6.7 million in Q4 and USD 30.3 million for FY 2025, up 13.56% in Q4 due to higher clinical trial expense from the SERENITY At-Home Phase 3 safety trial.
  • SG&A expense was USD 3.8 million in Q4 and USD 20.5 million for FY 2025, down 5.93% and 40.59%, respectively, driven by lower personnel, legal and professional fees, and reduced commercial and marketing costs following clinical reprioritization.
  • Net loss was USD 12.5 million in Q4 and USD 69.9 million for FY 2025, while cash and cash equivalents and restricted cash were USD 28.8 million at year-end; management said an IGALMI at-home sNDA was submitted in January and the timeline supports potential approval as early as year-end 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603270700PRIMZONEFULLFEED9679606) on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment